International Conference on Antidepressant Drugs, Prescription Trends and Statistics

ICADPTS

15th May – 16th May 2027 San Francisco, USA

Official Invitation Letter Available

An official invitation letter will be provided upon successful registration for your participation in the conference.

Benefits of Registering as Listener

Access to All Conference Sessions

Plenary, keynote and parallel sessions

Networking Opportunities

Connect with global educators & researchers

Certificate of Participation

Digital certificate of participation

Invitation Letter Support

Official invitation letter after successful registration

Conference Kit / Digital Materials

E-proceedings & resource materials

Access to Keynote Sessions

Learn from leading experts & scholars

Credit Card

Debit Card

Net Banking

Cash Card

Unified Payments

Select Registration Mode

Standard / Physical Participation USD

Join us on-site for keynotes, talks, workshops, networking, conference kit and certificate.

Virtual Participation USD

Participate online via live streaming. Includes live access to all sessions, digital materials and certificate.

Participant Details

Full Name *

Email Address *

Mobile Number with Country Code *

City *

State *

Country *

Zip / Postal Code *

Address *

Coupon Code

Terms & Condition

I agree to the Terms & Conditions and Refund & Cancellation Policy.

Read the full Terms & Conditions

Registration Summary

Conference ICADPTS

Date 15th May – 16th May 2027

Location San Francisco, USA

Participation Type Listener

Organizer Science Leagues

Registration Mode Standard / Physical

Registration Fee USD 0.00

Bank Convenience Charges (5.8%)i USD 0.00

Calculated based on 5.8% of the registration fee

Discount USD 0.00

Total Payable USD 0.00

100% Secure Payment

Your payment information is encrypted and processed securely.

Conference Session Tracks

Aligned with UN Sustainable Development Goals

The conference's session tracks effectively support the following SDGs.

01 Advancements in Psychopharmacology +

This track focuses on the latest research in psychopharmacology, particularly concerning antidepressant drugs. It aims to explore the mechanisms of action, efficacy, and safety profiles of various antidepressants.

SDG 3 SDG 4

02 Prescription Trends in Antidepressant Use +

This session will analyze recent trends in the prescription of antidepressants across different demographics and regions. It will provide insights into the factors influencing prescribing behaviors and patterns.

SDG 3 SDG 10

03 Statistical Analyses of Antidepressant Prescribing +

This track emphasizes the application of statistical methods to understand antidepressant prescribing trends. Participants will present quantitative analyses that highlight significant patterns and correlations.

SDG 3 SDG 9

04 Societal and Cultural Influences on Antidepressant Use +

This session will examine how societal norms and cultural contexts affect the prescription and consumption of antidepressants. Discussions will include the stigma surrounding mental health and its impact on treatment choices.

SDG 3 SDG 10

05 Environmental Impacts of Antidepressant Consumption +

This track will explore the environmental consequences of increased antidepressant use, including pharmaceutical waste and its effects on ecosystems. Researchers will present findings on the ecological footprint of these medications.

SDG 12 SDG 15

06 National Trends in Antidepressant Prescribing +

This session will focus on national-level data regarding antidepressant prescribing practices. It will highlight variations in prescription rates and the implications for public health policy.

SDG 3 SDG 10

07 Secular Trends in Antidepressant Use +

This track will investigate long-term secular trends in the use of antidepressants over the past decades. Presentations will cover shifts in prescribing habits and their implications for mental health treatment.

SDG 3 SDG 4

08 Types and Classifications of Antidepressants +

This session will provide an overview of the various types of antidepressants, including SSRIs, SNRIs, and atypical antidepressants. Discussions will focus on their clinical applications and comparative effectiveness.

SDG 3 SDG 4

09 Adverse Effects and Safety Profiles of Antidepressants +

This track will delve into the adverse effects associated with antidepressant use, emphasizing the importance of monitoring and managing these risks. Researchers will present data on safety profiles and patient outcomes.

SDG 3 SDG 4

10 Innovative Approaches to Antidepressant Therapy +

This session will explore novel therapeutic approaches and emerging treatments in the field of antidepressants. It will include discussions on personalized medicine and the integration of alternative health strategies.

SDG 3 SDG 9

11 Future Directions in Antidepressant Research +

This track will focus on the future of antidepressant research, including potential new drug developments and therapeutic targets. Participants will discuss the implications of ongoing research for clinical practice and patient care.

SDG 3 SDG 9